-
OX40 Agonists: Revitalizing the Immune Response in Cancer(Post)
Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40
Ivuxolimab: Redefining Cancer Immunotherapy and Research(Post)Quick Facts About IvuxolimabWhat is ivuxolimab?Ivuxolimab is a monoclonal antibody targeting CD47, a "don't eat me" signal that cancer cells exploit to evade immune destruction.How does
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik
Immunohistochemical Staining, Antibodies & Buffers(Page) TGF-Beta SMAD Signalling Pathway: Function, Readouts and Assays(Post)Almost all of the TGF-β in a tissue is already there, and almost none of it is active. That single fact reorganises how the pathway should be studied. Unlike most cytokines, TGF-β is deposited into t
Optimizing Organoid Culture Conditions: Paving the Way for Revolutionary Advances in Biomedical Research(Post)In the dynamic landscape of biomedical research, organoids have emerged as a groundbreaking tool, offering three-dimensional (3D) models that mimic the complex architecture and functionality of hu
Understanding Blotchy Western Blots: Causes and Remedies(Post)Western blotting is a powerful and widely used technique in molecular biology, essential for detecting and quantifying specific proteins in complex biological samples. However, despite its popu
Spike-Recovery-ELISA: Protokoll, Berechnung und Akzeptanzgrenzen(Post)Spike-Recovery-ELISA: Protokoll, Berechnung und Akzeptanzgrenzen Spike-Recovery prüft, ob Ihre Probenmatrix die ELISA-Messung verfälscht. Sie versetzen eine bekannte Menge Antigen in Ihre Probe und p
ELISA-Kalibrierung mit 4PL: Laborcheckliste, Kontrollen und Hilfe(Post)ELISA-Kalibrierung mit 4PL: Laborcheckliste, Kontrollen und Hilfe Für symmetrische ELISA-Standardkurven ist das 4-Parameter-logistische Modell (4PL) der praxisgerechte Standard. Starte mit 4PL, prüfe
Flow Cytometry Antibodies(Page)Flow Cytometry Antibodies | 16,900+ Conjugates & Panel Builder | Assay Genie
Breakthrough Discovery: Epstein-Barr Virus Identified as Primary Trigger for Lupus(Post)Breakthrough Discovery: Epstein-Barr Virus Identified as Primary Trigger for Lupus A groundbreaking study published in November 2025 has provided the most definitive evidence to date that the common E
C-Reactive Protein (CRP): Function, Levels & What They Mean(Post)Biomarkers · InflammationC-Reactive Protein (CRP): Structure, Function and Clinical UseCRP is the most widely measured marker of inflammation in medicine — fast to rise, fast to fall, and entirely non
Platinum based cancer drugs and next generation therapeutics(Post)Platinum based cancer drugs Despite nearly 50% of all anti-cancer treatments being platinum-based, there is an urgent need to develop novel therapeutics
Hijacking the Skull's Gateways: A New 'Backdoor' for Brain Drug Delivery(Post)For decades, the brain has been considered an immune sanctuary, protected by the formidable blood-brain barrier. This intricate defense system, while vital for safeguarding our most complex organ, ha
Types of ELISA: Direct, Indirect, Sandwich & Competitive Compared(Post)Written by Seán Mac Fhearraigh, PhD • Updated: 19 May 2026 • ~9 min read Quick Answer The five main types of ELISA are sandwich, competitive, direct, indirect and multiplex. Sandwich ELISA is
Cure CLCN4 2025(Post)Cure CLCN4 2025Assay Genie was honored to attend and present at the 2025 Cure CLCN4 Scientific Conference, held on May 19–20 at Friends House in London and online. This annual event, now
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research(Post)Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does